Clinical Trial Update: Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating docetaxel, prednisone, and pasireotide in metastatic hormone-resistant prostate cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• PREDNISONE (Prednisone)
• Pasireotide (pasireotide)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-03-25